bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from The CARMA3–Bcl10–MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor–Positive Breast Cancer
Authors: Ekambaram Prasanna , Lee Jia-Ying (Lloyd) , Hubel Nathaniel E. , Hu Dong , Yerneni Saigopalakrishna , Campbell Phil G. , Pollock Netanya , Klei Linda R. , Concel Vincent J. , Delekta Phillip C. , Chinnaiyan Arul M. , Tomlins Scott A. , Rhodes Daniel R. , Priedigkeit Nolan , Lee Adrian V. , Oesterreich Steffi , McAllister-Lucas Linda M. , Lucas Peter C.
Published: April 2023

AGTR1 expression in breast cancer specimens from METABRIC and TCGA, and in breast cancer cell lines.
Supplementary Figures S1-S12 from Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells through PKC Activation
Authors: Yu Zu-Yin , Xiao He , Wang Li-Mei , Shen Xing , Jing Yu , Wang Lin , Sun Wen-Feng , Zhang Yan-Feng , Cui Yu , Shan Ya-Jun , Zhou Wen-Bing , Xing Shuang , Xiong Guo-Lin , Liu Xiao-Lan , Dong Bo , Feng Jian-Nan , Wang Li-Sheng , Luo Qing-Liang , Zhao Qin-Shi , Cong Yu-Wen
Published: April 2023

Differentiation induction activity of vibsanine A and its analogues on HL-60 Cells (S1); Characterization of differentiation-inducing activity of vibsanine A (S2); Vibsanine A-induced growth inhibition of myeloid leukemia cells (S3); Gene expression profiles in HL-60 cells (S4); Downregulation of PKC isozymes induced by vibsanine A and PMA (S5); Effect of different PKC inhibitors on the PMA-induced differentiation (S6); [3H]PDBu Binding (S7); The 3-D complex structures of PKC isoforms and vibsanine A (S8); Ectopic c-Myc expression blocked G1 cell cycle arrest by vibsanine A (S9); Ectopic c-Myc expression effectively inhibited cellular differentiation by vibsanine A in infected NB4 cells (S10); Effect of vibsanine A treatment on the body weight of mouse xenograft models of AML (S11); Effect of vibsanine A on PMA-induced inflammatory responses in CD-1 mice (S12).
Supplementary Table S1 from Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells
Authors: Wang Yu , Dehigaspitiya Dilani C. , Levine Paul M. , Profit Adam A. , Haugbro Michael , Imberg-Kazdan Keren , Logan Susan K. , Kirshenbaum Kent , Garabedian Michael J.
Published: April 2023

IC50 of enzalutamide and MPC6 in prostate cancer cell lines.
Supp Fig 2 from Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Authors: Bachegowda Lohith , Morrone Kerry , Winski Shannon L. , Mantzaris Ioannis , Bartenstein Matthias , Ramachandra Nandini , Giricz Orsi , Sukrithan Vineeth , Nwankwo George , Shahnaz Samira , Bhagat Tushar D. , Bhattacharyya Sanchari , Assal Amer , Shastri Aditi , Gordon-Mitchell Shanisha , Pellagatti Andrea , Boultwood Jacqueline , Schinke Carolina , Yu Yiting , Guha Chandan , Rizzi James , Garrus Jennifer , Brown Suzy , Wollenberg Lance , Hogeland Grant , Wright Dale , Munson Mark , Rodriguez Mareli , Gross Stefan , Chantry David , Zou Yiyu , Platanias Leonidas C. , Burgess Laurence E. , Pradhan Kith , Steidl Ulrich , Verma Amit
Published: April 2023

Knockdown of Angpt1 does not lead to inhibition of leukemic cell viability
Supplementary Table 1 from Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma
Authors: Allain Coralie , Angenard Gaëlle , Clément Bruno , Coulouarn Cédric
Published: April 2023

Characteristics of the 28 liver-oriented HCC microarray datasets (MDS).
Supplementary Tables from Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
Authors: Hanker Ariella B. , Estrada Mónica Valeria , Bianchini Giampaolo , Moore Preston D. , Zhao Junfei , Cheng Feixiong , Koch James P. , Gianni Luca , Tyson Darren R. , Sánchez Violeta , Rexer Brent N. , Sanders Melinda E. , Zhao Zhongming , Stricker Thomas P. , Arteaga Carlos L.
Published: April 2023

Supplementary Table 1. List of antibodies used for immunoblotting. Supplementary Table 2. Patient biopsies used for IHC analysis. Supplementary Table 3. List of genes that are significantly upregulated in TPB-resistant tumors relative to untreated parental tumors. Supplementary Table 4. Expression of ECM/cell adhesion genes in pre-treatment tumor biopsies from patients in the NeoSphere trial.
Supplemental Table 1 from Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort
Authors: Fortner Renée T. , Schock Helena , Kaaks Rudolf , Lehtinen Matti , Pukkala Eero , Lakso Hans-Åke , Tanner Minna , Kallio Raija , Joensuu Heikki , Korpela Jaana , Toriola Adetunji T. , Hallmans Göran , Grankvist Kjell , Zeleniuch-Jacquotte Anne , Toniolo Paolo , Lundin Eva , Surcel Heljä-Marja
Published: April 2023

Supplemental Table 1. Distribution of Covariates by hCG Quartiles: Finnish Maternity Cohort
Supplmentary Figure S4 from ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
Authors: Muranen Taru , Selfors Laura M. , Hwang Julie , Gallegos Lisa L. , Coloff Jonathan L. , Thoreen Carson C. , Kang Seong A. , Sabatini David M. , Mills Gordon B. , Brugge Joan S.
Published: April 2023

Both, p38/MAPK, and ERK/MEK pathway contribute to MYC and YAP up-regulation in resistant cell lines.
Supplementary Figure S3 from Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
Authors: Lorvik Kristina Berg , Hammarström Clara , Fauskanger Marte , Haabeth Ole Audun Werner , Zangani Michael , Haraldsen Guttorm , Bogen Bjarne , Corthay Alexandre
Published: April 2023

This file contains visualization of eosinophils and mast cells at the tumor site upon Th2 ACT: Supplementary Figure S3
Supplementary Figure S1 from Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
Authors: Lorvik Kristina Berg , Hammarström Clara , Fauskanger Marte , Haabeth Ole Audun Werner , Zangani Michael , Haraldsen Guttorm , Bogen Bjarne , Corthay Alexandre
Published: April 2023

This file contains an evaluation of the number of Th2 cells required for ACT: Supplementary Figure S1
Suppl. Fig. Legends from SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance
Authors: Orlacchio Arturo , Ranieri Michela , Brave Martina , Arciuch Valeria Antico , Forde Toni , De Martino Daniela , Anderson Karen E. , Hawkins Phillip , Di Cristofano Antonio
Published: April 2023

Suppl. Fig. Legends
Figure S3 from SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance
Authors: Orlacchio Arturo , Ranieri Michela , Brave Martina , Arciuch Valeria Antico , Forde Toni , De Martino Daniela , Anderson Karen E. , Hawkins Phillip , Di Cristofano Antonio
Published: April 2023

Sgk3 depletion is less effective than Sgk1 depletion in impairing PI3K-dependent thyroid cancer cell proliferation.
Supplementary Figures 1 and 2 from Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression
Authors: Shibata Tomohiro , Watari Kosuke , Izumi Hiroto , Kawahara Akihiko , Hattori Satoshi , Fukumitsu Chihiro , Murakami Yuichi , Takahashi Ryuji , Toh Uhi , Ito Ken-ichi , Ohdo Shigehiro , Tanaka Maki , Kage Masayoshi , Kuwano Michihiko , Ono Mayumi
Published: April 2023

Supplementary Figure S1. Effect of YBX1 on ESR protein expression and ubiquitination of ESR. Supplementary Figure S2. Effect of ESR knockdown on ERBB2 expression.
Supplementary Figures S1-S10 from Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra
Authors: Chmielecki Juliann , Bailey Mark , He Jie , Elvin Julia , Vergilio Jo-Anne , Ramkissoon Shakti , Suh James , Frampton Garrett M. , Sun James X. , Morley Samantha , Spritz Daniel , Ali Siraj , Gay Laurie , Erlich Rachel L. , Ross Jeffrey S. , Buxhaku Joana , Davies Hilary , Faso Vinny , Germain Alexis , Glanville Blair , Miller Vincent A. , Stephens Philip J. , Janeway Katherine A. , Maris John M. , Meshinchi Soheil , Pugh Trevor J. , Shern Jack F. , Lipson Doron
Published: April 2023

Long tail distribution of the top 50 altered genes in pediatric sarcoma (S1); Long tail distribution of the top 50 altered genes in pediatric extracranial embryonal tumors (S2); Long tail distribution of the top 50 altered genes in pediatric brain tumors (S3); Long tail distribution of the top 50 altered genes in pediatric heme malignancies (S4); Long tail distribution of the top 50 altered genes in pediatric carcinomas (S5); Long tail distribution of the top 50 altered genes in pediatric gonadal tumors (S6); Known fusions identified in the pediatric cohort (S7); Tileplots showing the pattern of co-occurring alterations with novel MLL3 mutations (S8); Tileplot showing the pattern of co-occurring alterations with a novel PRSS1 mutation (S9); Tileplot showing the pattern of co-occurring alterations with novel DKC1 deletions (S10).
Supplementary Tables 1-3 and Figures 1-9 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Authors: Fleuren Emmy D.G. , Vlenterie Myrella , van der Graaf Winette T.A. , Hillebrandt-Roeffen Melissa H.S. , Blackburn James , Ma Xiuquan , Chan Howard , Magias Mandy C. , van Erp Anke , van Houdt Laurens , Cebeci Sabri A.S. , van de Ven Amy , Flucke Uta E. , Heyer Erin E. , Thomas David M. , Lord Christopher J. , Marini Kieren D. , Vaghjiani Vijesh , Mercer Tim R. , Cain Jason E. , Wu Jianmin , Versleijen-Jonkers Yvonne M.H. , Daly Roger J.
Published: April 2023

This file contains the following supplemental data: Supplemental Table 1. Specific information for MTT cell viability assays with single agents. Supplemental Table 2. Patient characteristics of synovial sarcoma cohort. Supplemental Table 3. Specifications of antibodies used for IHC and Western Blot. Supplemental Table 6. Summary of SS cell line sensitivity to specific tyrosine kinase inhibitors. Supplemental Figure 1. Integrated protein-protein interaction network for all sarcoma subgroups. Supplemental Figure 2. ALK expression and phosphorylation in ES and RMS cell lines. Supplemental Figure 3. Schematic representation of ALK exon 2-17 deletion in Aska-SS cells. Supplemental Figure 4. Deglycosylation of ALK in Aska-SS cells. Supplemental Figure 5. SS cell line sensitivity to foretinib, gefitinib and erlotinib. Supplemental Figure 6. Effects of ALK inhibition on cell cycle and apoptotic markers in Aska-SS cells. Supplemental Figure 7. Effects of ALK inhibition on Aska-SS in vivo tumors. Supplemental Figure 8. ALK, MET and PDGFRA mRNA expression in clinical SS versus other STS samples. Supplemental Figure 9. ALK IHC and patient characteristics of ALK-positive SS tumors. Supplemental Figure 10. Effect of PDGFR and MET inhibition on apoptosis in Yamato-SS cells. Brief sections of Supplementary methods and Supplementary references are included in this file as well.
Movie S3 from Liver Metastasis Is Facilitated by the Adherence of Circulating Tumor Cells to Vascular Fibronectin Deposits
Authors: Barbazán Jorge , Alonso-Alconada Lorena , Elkhatib Nadia , Geraldo Sara , Gurchenkov Vasily , Glentis Alexandros , van Niel Guillaume , Palmulli Roberta , Fernández Beatriz , Viaño Patricia , Garcia-Caballero Tomas , López-López Rafael , Abal Miguel , Vignjevic Danijela Matic
Published: April 2023

Movie S3 from Liver Metastasis Is Facilitated by the Adherence of Circulating Tumor Cells to Vascular Fibronectin Deposits
Movie S2 from Liver Metastasis Is Facilitated by the Adherence of Circulating Tumor Cells to Vascular Fibronectin Deposits
Authors: Barbazán Jorge , Alonso-Alconada Lorena , Elkhatib Nadia , Geraldo Sara , Gurchenkov Vasily , Glentis Alexandros , van Niel Guillaume , Palmulli Roberta , Fernández Beatriz , Viaño Patricia , Garcia-Caballero Tomas , López-López Rafael , Abal Miguel , Vignjevic Danijela Matic
Published: April 2023

Movie S2 from Liver Metastasis Is Facilitated by the Adherence of Circulating Tumor Cells to Vascular Fibronectin Deposits
Supplementary figures from SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells
Authors: Kurtsdotter Idha , Topcic Danijal , Karlén Alexandra , Singla Bhumica , Hagey Daniel W. , Bergsland Maria , Siesjö Peter , Nistér Monica , Carlson Joseph W. , Lefebvre Veronique , Persson Oscar , Holmberg Johan , Muhr Jonas
Published: April 2023

This file contains Figures S1-S6. Figure S1 shows proliferation of neural stem cells after in utero electroporation of Sox5, Sox6 or Sox21, and the successful activation of viral vector expression by CRE enzyme. Figure S2 shows reduction of SOX5/6/21 levels after intracranial ARC injection. H
supplementary methods and figures from Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells
Authors: Feeley Kyle P. , Adams Clare M. , Mitra Ramkrishna , Eischen Christine M.
Published: April 2023

File contains supplementary methods, primer sequences, supplementary figures and legends. Supplementary Figure S1 is the confirmation of p53-null status. Supplementary Figure S2 shows loss of Mdm2 induces a G2/M cell cycle arrest. Supplementary Figure S3 shows loss of Mdm2 induces a G2/M cell cycle arrest in vivo. Supplementary Figure S4 shows Mdm2 deletion induces apoptosis in vivo. Supplementary Figure S5 shows gene set enrichment analyses for apoptosis and p53 pathway genes.
Figure S3 from Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy
Authors: Ciccolini Joseph , Barbolosi Dominique , Meille Christophe , Lombard Aurélie , Serdjebi Cindy , Giacometti Sarah , Padovani Laetitia , Pasquier Eddy , André Nicolas
Published: April 2023

Pharmacokinetics in silico simulation for gemcitabine monotherapy
Figure S1 from Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy
Authors: Ciccolini Joseph , Barbolosi Dominique , Meille Christophe , Lombard Aurélie , Serdjebi Cindy , Giacometti Sarah , Padovani Laetitia , Pasquier Eddy , André Nicolas
Published: April 2023

Difference of sensitivity to gemcitabine between neuroblastoma and endothelial cells in vitro
Supplementary Figure 3 from Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine
Authors: Shi Yanxia , Steppi Albert , Cao Ye , Wang Jianan , He Max M. , Li Liren , Zhang Jinfeng
Published: April 2023

Figure S3: The overlap of differentially expressed genes among different comparisons. Left: overlapping among overall comparison (All), early stage comparison (ES), and late stage comparison (LS); Right: overlapping among overall comparison (All), Luminal subtype (LA), HER2 subtype (HER2), and triple-negative subtype (TN).
Figures S1-S8 from Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation
Authors: Malakar Pushkar , Shilo Asaf , Mogilevsky Adi , Stein Ilan , Pikarsky Eli , Nevo Yuval , Benyamini Hadar , Elgavish Sharona , Zong Xinying , Prasanth Kannanganattu V. , Karni Rotem
Published: April 2023

Figure S1: Knockdown of MALAT1 inhibits proliferation of liver progenitor and HCC cells. Figure S2: Effect of MALAT1 expression on splicing of endogenous SRSF1 targets. Figure S3. Differential gene expression based on RNA-seq data. Figure S4. Enriched pathways and networks activated by overexpression of MALAT1 based on RNA-seq analysis. Figure S5 Enriched pathways activated by MALAT1 overexpression based on RNA-seq analysis. Figure S6. Validation of MALAT1 up- and down-regulated genes identified by RNA-seq analysis. Figure S7. Knockdown of MALAT1 down-regulates c-Myc protein levels. Figure S8. Knockdown of SRSF1 inhibits oncogenesis downstream to MALAT1 and only partially inhibits transformation by oncogenic Ras.
Supplementary Figure 3 from PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer
Authors: Cox Orla T. , Edmunds Shelley J. , Simon-Keller Katja , Li Bo , Moran Bruce , Buckley Niamh E. , Bustamante-Garrido Milan , Healy Nollaig , O'Flanagan Ciara H. , Gallagher William M. , Kennedy Richard D. , Bernards René , Caldas Carlos , Chin Suet-Feung , Marx Alexander , O'Connor Rosemary
Published: April 2023

Related to Figures 2 and 3: Shows counts of distribution of IHC scores of PDLIM2 staining in RATHER cohort based on TNBC subtype. Includes analysis of TNBC subtypes of tissues in the RATHER cohorts in relation to PDLIM2 expression, a Kaplan Meier plot of breast cancer specific survival in relation to TNBC subtype, and correlation plot of PDLIM2 mRNA and protein expression in the RATHER cohorts. Examples of nuclear PDLIM2 expression in stromal/infiltrating cells are also shown.
Supplementary Table S2 from Novel SEC61G–EGFR Fusion Gene in Pediatric Ependymomas Discovered by Clonal Expansion of Stem Cells in Absence of Exogenous Mitogens
Authors: Servidei Tiziana , Meco Daniela , Muto Valentina , Bruselles Alessandro , Ciolfi Andrea , Trivieri Nadia , Lucchini Matteo , Morosetti Roberta , Mirabella Massimiliano , Martini Maurizio , Caldarelli Massimo , Lasorella Anna , Tartaglia Marco , Riccardi Riccardo
Published: April 2023

IC50 values of EGFR TKIs gefitinib and AEE788 in paired MD and MI ependymoma lines
Supplementary Table S5 from Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients
Authors: Wang Lei , Felts Sara J. , Van Keulen Virginia P. , Scheid Adam D. , Block Matthew S. , Markovic Svetomir N. , Pease Larry R. , Zhang Yuji
Published: April 2023

The information of the trans-regulatory lncRNAs associated with immune responses and 3 mRNA translation pathways in CD4+ PBC.
Suppl Figure 3 from BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC
Authors: Leonard Brandon , Brand Toni M. , O'Keefe Rachel A. , Lee Eliot D. , Zeng Yan , Kemmer Jacquelyn D. , Li Hua , Grandis Jennifer R. , Bhola Neil E.
Published: April 2023

Determination and validation of BRD4 expression in acquired cetuximab-resistant HNSCC models.
Figure S1 from The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation
Authors: Weissmann Simon , Cloos Paul A. , Sidoli Simone , Jensen Ole N. , Pollard Steven , Helin Kristian
Published: April 2023

Supplementary Figure S1 contains information about mutations in CIC as well as additional data from mouse ESCs: targeting strategy for CRISPR/Cas9 mediated deletion, gene ontology of CIC target genes and rescue of Cic KO cells with WT and mutant CIC protein.
Figure S1 from Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma
Authors: Baird Jason R. , Bell R. Bryan , Troesch Victoria , Friedman David , Bambina Shelly , Kramer Gwen , Blair Tiffany C. , Medler Terry , Wu Yaping , Sun Zhaoyu , de Gruijl Tanja D. , van de Ven Rieneke , Leidner Rom S. , Crittenden Marka R. , Gough Michael J.
Published: April 2023

Patient characteristics
Table S2 from The Autotaxin—Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis
Authors: Magkrioti Christiana , Oikonomou Nikos , Kaffe Eleanna , Mouratis Marios-Angelos , Xylourgidis Nikos , Barbayianni Iliana , Megadoukas Petros , Harokopos Vaggelis , Valavanis Christos , Chun Jerold , Kosma Alexandra , Stathopoulos Georgios T. , Bouros Evangelos , Bouros Demosthenes , Syrigos Konstantinos , Aidinis Vassilis
Published: April 2023

Clinicopathological characteristics of LC patients with serum samples
On line data supplement from The Autotaxin—Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis
Authors: Magkrioti Christiana , Oikonomou Nikos , Kaffe Eleanna , Mouratis Marios-Angelos , Xylourgidis Nikos , Barbayianni Iliana , Megadoukas Petros , Harokopos Vaggelis , Valavanis Christos , Chun Jerold , Kosma Alexandra , Stathopoulos Georgios T. , Bouros Evangelos , Bouros Demosthenes , Syrigos Konstantinos , Aidinis Vassilis
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S1 from Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells
Authors: Bélanger François , Fortier Emile , Dubé Maxime , Lemay Jean-François , Buisson Rémi , Masson Jean-Yves , Elsherbiny Abdelhamid , Costantino Santiago , Carmona Euridice , Mes-Masson Anne-Marie , Wurtele Hugo , Drobetsky Elliot
Published: April 2023

Supplementary Figure S1 shows clonogenic survival curves for ovarian cancer cell lines exposed to different genotoxic agents.
Supplementary Materials and Figure legends S1-S7 from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging
Authors: Stangl Stefan , Tei Lorenzo , De Rose Francesco , Reder Sybille , Martinelli Jonathan , Sievert Wolfgang , Shevtsov Maxim , Öllinger Rupert , Rad Roland , Schwaiger Markus , D'Alessandria Calogero , Multhoff Gabriele
Published: April 2023

Synthesis, characterization and in vitro and in vivo stability testing of TPP-PEG24-DFO[89Zr] and histological analysis of a benign fibroblast hyperplasia
Figure S2 from Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin
Authors: Hiller Björn , Hoppe Anja , Haase Christa , Hiller Christina , Schubert Nadja , Müller Werner , Reijns Martin A.M. , Jackson Andrew P. , Kunkel Thomas A. , Wenzel Jörg , Behrendt Rayk , Roers Axel
Published: April 2023

Spontaneous type I IFN response and inflammation in Rnaseh2EKO skin.
Supplementary Figures and Table Legends from Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer
Authors: Ubellacker Jessalyn M. , Baryawno Ninib , Severe Nicolas , DeCristo Molly J. , Sceneay Jaclyn , Hutchinson John N. , Haider Marie-Therese , Rhee Catherine S. , Qin Yuanbo , Gregory Walter M. , Garrido-Castro Ana C. , Holen Ingunn , Brown Janet E. , Coleman Robert E. , Scadden David T. , McAllister Sandra S.
Published: April 2023

Supplementary Figures and Table Legends to support primary figures
Supplemental Tables from Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition
Authors: Fuentes Natividad R. , Mlih Mohamed , Barhoumi Rola , Fan Yang-Yi , Hardin Paul , Steele Trevor J. , Behmer Spencer , Prior Ian A. , Karpac Jason , Chapkin Robert S.
Published: April 2023

Contains Supplemental Table 1, drosophila diet fatty acid composition. Supplemental Table 2, mouse diet composition. Supplemental Table 3, mouse diet fatty acid composition. Supplemental Table 4, incorporation of exogenous fatty acids into murine colonic crypt membrane phospholipids. Supplemental Table 5, incorporation of exogenous corn oil fatty acids into Drosophila gut membrane phospholipids.
Table S1 from MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells
Authors: Bayley Rachel , Blakemore Daniel , Cancian Laila , Dumon Stephanie , Volpe Giacomo , Ward Carl , Almaghrabi Ruba , Gujar Jidnyasa , Reeve Natasha , Raghavan Manoj , Higgs Martin R. , Stewart Grant S. , Petermann Eva , García Paloma
Published: April 2023

Gene expression analysis comapring Mybl2 high vs Mybl2 low
Figure S5 from Heterozygosity of Chaperone Grp78 Reduces Intestinal Stem Cell Regeneration Potential and Protects against Adenoma Formation
Authors: van Lidth de Jeude Jooske F. , Spaan Claudia N. , Meijer Bartolomeus J. , Smit Wouter L. , Soeratram Tanya T.D. , Wielenga Mattheus C.B. , Westendorp B. Florien , Lee Amy S. , Meisner Sander , Vermeulen Jacqueline L.M. , Wildenberg Manon E. , van den Brink Gijs R. , Muncan Vanesa , Heijmans Jarom
Published: April 2023

Supplementary Figure S5
Supplementary Information from Mouse Homolog of the Human TP53 R337H Mutation Reveals Its Role in Tumorigenesis
Authors: Park Ji-Hoon , Li Jie , Starost Matthew F. , Liu Chengyu , Zhuang Jie , Chen Jichun , Achatz Maria I. , Kang Ju-Gyeong , Wang Ping-yuan , Savage Sharon A. , Hwang Paul M.
Published: April 2023

This Supplemental Information file contains the Materials and Methods for the supplementary tables and figures merged into this same file. These are Tables 1-3 which show primer sequences, observed genotypes and gender of p53 R334H mouse crossings, and incidence of adrenal abnormalities; and Figures S1-S9 which provide additional data on mouse phenotype, DEN metabolism, tumor LOH, DNA damage time course, oncogene-induced senescence in MEFs, p53 expression levels, and further oligomerization studies.
Supplementary Figures and Tables from Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow–Resident Melanoma CTCs
Authors: Vishnoi Monika , Boral Debasish , Liu Haowen , Sprouse Marc L. , Yin Wei , Goswami-Sewell Debalina , Tetzlaff Michael T. , Davies Michael A. , Oliva Isabella C. Glitza , Marchetti Dario
Published: April 2023

Supplementary Figures and Tables
Fig, S5 from RIPK1 Binds MCU to Mediate Induction of Mitochondrial Ca2+ Uptake and Promotes Colorectal Oncogenesis
Authors: Zeng Fanxin , Chen Xiao , Cui Weiyi , Wen Wei , Lu Fujian , Sun Xueting , Ma Dongwei , Yuan Ye , Li Zezhong , Hou Ning , Zhao Hong , Bi Xinyu , Zhao Jianjun , Zhou Jianguo , Zhang Yan , Xiao Rui-Ping , Cai Jianqiang , Zhang Xiuqin
Published: April 2023

Figure S5. MICU1 is Down-regulated in CRC. (A, B) Representative western blots and averaged data for MICU1 from normal and CRC tissue, n = 7. Data are mean {plus minus} SEM. of three independent experiments. *p Ë, 0.05, normal vs CRC.
Supplementary Tables from Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity
Authors: Muralidhar Sathya , Filia Anastasia , Nsengimana Jérémie , Poźniak Joanna , O'Shea Sally J. , Diaz Joey M. , Harland Mark , Randerson-Moor Juliette A. , Reichrath Jörg , Laye Jonathan P. , van der Weyden Louise , Adams David J. , Bishop D.T. , Newton-Bishop Julia
Published: April 2023

Supplementary Tables 1-8
Figure S1 from The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right
Authors: Park Derek S. , Robertson-Tessi Mark , Luddy Kimberly A. , Maini Philip K. , Bonsall Michael B. , Gatenby Robert A. , Anderson Alexander R.A.
Published: April 2023

RECIST outcomes under different immune expansion times. Longer times of T cell expansion lead to more favorable outcomes for aggressive tumors when treated within the Goldilocks Window.
Supplementary Figure 5 from Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression
Authors: Lucchesi Christopher A. , Zhang Jin , Ma Buyong , Chen Mingyi , Chen Xinbin
Published: April 2023

Pep8 sensitizes tumor cells to doxorubicin induced senescence.
Figure S8 from Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861
Authors: Pedrosa Ana-Rita , Bodrug Natalia , Gomez-Escudero Jesus , Carter Edward P. , Reynolds Louise E. , Georgiou Paraskivi Natalia , Fernandez Isabelle , Lees Delphine M. , Kostourou Vassiliki , Alexopoulou Annika N. , Batista Silvia , Tavora Bernardo , Serrels Bryan , Parsons Maddy , Iskratsch Thomas , Hodivala-Dilke Kairbaan M.
Published: April 2023

Supplementary Figure 8. Loss of endothelial cell FAK-Y397 or FAK-Y861-phosphorylation affect protein profile expression and p-Src response to Vegf-a and Ang-2.
Supplementary Figure 3 from Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression
Authors: Lucchesi Christopher A. , Zhang Jin , Ma Buyong , Chen Mingyi , Chen Xinbin
Published: April 2023

Pep8 inhibits tumor cell growth in Rbm38- and p53-dependent manners.
Figure S5 from S100A10 Is a Critical Mediator of GAS6/AXL–Induced Angiogenesis in Renal Cell Carcinoma
Authors: Xiao Yiren , Zhao Hongjuan , Tian Lei , Nolley Rosalie , Diep Anh N. , Ernst Anne , Fuh Katherine C. , Miao Yu Rebecca , von Eyben Rie , Leppert John T. , Brooks James D. , Peehl Donna M. , Giaccia Amato J. , Rankin Erinn B.
Published: April 2023

Kidney cancer ccRCC patient information and sAXL treatment in sensitizing ccRCC PDX tumors to TKI therapy.
Figure S3 from The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11
Authors: Liu Tong , Jiang Le , Tavana Omid , Gu Wei
Published: April 2023

The loss of OTUB1 induces ferroptosis in H1299 cells
Figure S2 from The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11
Authors: Liu Tong , Jiang Le , Tavana Omid , Gu Wei
Published: April 2023

Stabilization of SLC7A11 by OTUB1
Figure S8 from DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs
Authors: Oshima Go , Poli Elizabeth C. , Bolt Michael J. , Chlenski Alexandre , Forde Martin , Jutzy Jessica M.S. , Biyani Neha , Posner Mitchell C. , Pitroda Sean P. , Weichselbaum Ralph R. , Khodarev Nikolai N.
Published: April 2023

Cancer cells MCF7 with strong response to 5-Aza-dC have hypermethylated MEG3-DMR promoter
Figure S2 from Prolactin Promotes Fibrosis and Pancreatic Cancer Progression
Authors: Tandon Manuj , Coudriet Gina M. , Criscimanna Angela , Socorro Mairobys , Eliliwi Mouhanned , Singhi Aatur D. , Cruz-Monserrate Zobeida , Bailey Peter , Lotze Michael T. , Zeh Herbert , Hu Jing , Goffin Vincent , Gittes George K. , Biankin Andrew V. , Esni Farzad
Published: April 2023

The pancreas of adult prolactin deficient mice display no obvious abnormalities.
Figure S3 from p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis
Authors: Wang Fang , Qi Xiao-Mei , Wertz Ryan , Mortensen Matthew , Hagen Catherine , Evans John , Sheinin Yuri , James Michael , Liu Pengyuan , Tsai Susan , Thomas James , Mackinnon Alexander , Dwinell Michael , Myers Charles R. , Bartrons Bach Ramon , Fu Liwu , Chen Guan
Published: April 2023

Figure S3. Pancreatic p38ÃƒÅ½Ã,Â³ KO inhibits pancreatic cancer metastasis and decreases p-PFKFB3, PFKFB3, GLUT2, inflammatory cytokine expression and suppresses metabolic and other pancreatic cancer pathways in metastatic and/or primary Pdac.
Supplementary Figures and Tables from The Cancer-Associated ATM R3008H Mutation Reveals the Link between ATM Activation and Its Exchange
Authors: Milanovic Maja , Sprinzen Lisa , Menolfi Demis , Lee Ji-Hoon , Yamamoto Kenta , Li Yang , Lee Brian J. , Xu Jun , Estes Verna M. , Wang Dong , Mckinnon Peter J. , Paull Tanya T. , Zha Shan
Published: April 2023

Sup. Figures
Data from Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
Authors: Bobrie Angélique , Krumeich Sophie , Reyal Fabien , Recchi Chiara , Moita Luis F. , Seabra Miguel C. , Ostrowski Matias , Théry Clotilde
Published: April 2023

Abstract
During progression from single cancer cells to a tumor mass and metastases, tumor cells send signals that can subvert their tissue microenvironment. These signals involve soluble molecules and various extracellular vesicles, including a particular type termed exosomes. The specific roles of exosomes secreted in the tumor microenvironment, however, is unclear. The small GTPases RAB27A and RAB27B regulate exocytosis of multivesicular endosomes, which lead to exosome secretion, in human HeLa cells. Here, we used mouse models to show that Rab27a blockade in mammary carcinoma cells decreased secretion of exosomes characterized by endocytic markers, but also of matrix metalloproteinase 9, which is not associated with exosomes. Rab27a blockade resulted in decreased primary tumor growth and lung dissemination of a metastatic carcinoma (4T1), but not of a nonmetastatic carcinoma (TS/A). Local growth of 4T1 tumors required mobilization of a population of neutrophil immune cells induced by Rab27a-dependent secretion of exosomes together with a specific combination of cytokines and/or metalloproteinases. Our findings offer in vivo validation of the concept that exosome secretion can exert key pathophysiologic roles during tumor formation and progression, but they also highlight the idiosyncratic character of the tumor context. Cancer Res; 72(19); 4920–30. ©2012 AACR.
Data from Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Authors: Popova Tatiana , Manié Elodie , Rieunier Guillaume , Caux-Moncoutier Virginie , Tirapo Carole , Dubois Thierry , Delattre Olivier , Sigal-Zafrani Brigitte , Bollet Marc , Longy Michel , Houdayer Claude , Sastre-Garau Xavier , Vincent-Salomon Anne , Stoppa-Lyonnet Dominique , Stern Marc-Henri
Published: April 2023

Abstract
BRCA1 inactivation is a frequent event in basal-like breast carcinomas (BLC). However, BRCA1 can be inactivated by multiple mechanisms and determining its status is not a trivial issue. As an alternate approach, we profiled 65 BLC cases using single-nucleotide polymorphism arrays to define a signature of BRCA1-associated genomic instability. Large-scale state transitions (LST), defined as chromosomal break between adjacent regions of at least 10 Mb, were found to be a robust indicator of BRCA1 status in this setting. Two major ploidy-specific cutoffs in LST distributions were sufficient to distinguish highly rearranged BLCs with 85% of proven BRCA1-inactivated cases from less rearranged BLCs devoid of proven BRCA1-inactivated cases. The genomic signature we defined was validated in a second independent series of 55 primary BLC cases and 17 BLC-derived tumor cell lines. High numbers of LSTs resembling BRCA1-inactivated BLC were observed in 4 primary BLC cases and 2 BLC cell lines that harbored BRCA2 mutations. Overall, the genomic signature we defined predicted BRCA1/2 inactivation in BLCs with 100% sensitivity and 90% specificity (97% accuracy). This assay may ease the challenge of selecting patients for genetic testing or recruitment to clinical trials of novel emerging therapies that target DNA repair deficiencies in cancer. Cancer Res; 72(21); 5454–62. ©2012 AACR.
Data from Oxidative Stress-Regulated Lentiviral TK/GCV Gene Therapy for Lung Cancer Treatment
Authors: Leinonen Hanna M. , Ruotsalainen Anna-Kaisa , Määttä Ann-Marie , Laitinen Heidi M. , Kuosmanen Suvi M. , Kansanen Emilia , Pikkarainen Jere T. , Lappalainen Jari P. , Samaranayake Haritha , Lesch Hanna P. , Kaikkonen Minna U. , Ylä-Herttuala Seppo , Levonen Anna-Liisa
Published: April 2023

Abstract
Nuclear factor erythroid-2 related factor 2 (Nrf2) is a transcription factor that regulates protection against a wide variety of toxic insults to cells, including cytotoxic cancer chemotherapeutic drugs. Many lung cancer cells harbor a mutation in either Nrf2 or its inhibitor Keap1 resulting in permanent activation of Nrf2 and chemoresistance. In this study, we sought to examine whether this attribute could be exploited in cancer suicide gene therapy by using a lentiviral (LV) vector expressing herpes simplex virus thymidine kinase (HSV-TK/GCV) under the regulation of antioxidant response element (ARE), a cis-acting enhancer sequence that binds Nrf2. In human lung adenocarcinoma cells in which Nrf2 is constitutively overexpressed, ARE activity was found to be high under basal conditions. In this setting, ARE-HSV-TK was more effective than a vector in which HSV-TK expression was driven by a constitutively active promoter. In a mouse xenograft model of lung cancer, suicide gene therapy with LV-ARE-TK/GCV was effective compared with LV-PGK-TK/GCV in reducing tumor size. We conclude that ARE-regulated HSV-TK/GCV therapy offers a promising approach for suicide cancer gene therapy in cells with high constitutive ARE activity, permitting a greater degree of therapeutic targeting to those cells. Cancer Res; 72(23); 6227–35. ©2012 AACR.
Data from CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma
Authors: Saintigny Pierre , Massarelli Erminia , Lin Steven , Ahn Young-Ho , Chen Yulong , Goswami Sangeeta , Erez Baruch , O'Reilly Michael S. , Liu Diane , Lee J. Jack , Zhang Li , Ping Yuan , Behrens Carmen , Solis Soto Luisa M. , Heymach John V. , Kim Edward S. , Herbst Roy S. , Lippman Scott M. , Wistuba Ignacio I. , Hong Waun Ki , Kurie Jonathan M. , Koo Ja Seok
Published: April 2023

Abstract
CXCR2 in non–small cell lung cancer (NSCLC) has been studied mainly in stromal cells and is known to increase tumor inflammation and angiogenesis. Here, we examined the prognostic importance of CXCR2 in NSCLC and the role of CXCR2 and its ligands in lung cancer cells. The effect of CXCR2 expression on tumor cells was studied using stable knockdown clones derived from a murine KRAS/p53–mutant lung adenocarcinoma cell line with high metastatic potential and an orthotopic syngeneic mouse model and in vitro using a CXCR2 small-molecule antagonist (SB225002). CXCR2 protein expression was analyzed in tumor cells from 262 NSCLC. Gene expression profiles for CXCR2 and its ligands (CXCR2 axis) were analyzed in 52 human NSCLC cell lines and 442 human lung adenocarcinomas. Methylation of CXCR2 axis promoters was determined in 70 human NSCLC cell lines. Invasion and metastasis were decreased in CXCR2 knockdown clones in vitro and in vivo. SB225002 decreased invasion in vitro. In lung adenocarcinomas, CXCR2 expression in tumor cells was associated with smoking and poor prognosis. CXCR2 axis gene expression profiles in human NSCLC cell lines and lung adenocarcinomas defined a cluster driven by CXCL5 and associated with smoking, poor prognosis, and RAS pathway activation. Expression of CXCL5 was regulated by promoter methylation. The CXCR2 axis may be an important target in smoking-related lung adenocarcinoma. Cancer Res; 73(2); 571–82. ©2012 AACR.
Data from Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination
Authors: Aarntzen Erik H.J.G. , De Vries I. Jolanda M. , Lesterhuis W. Joost , Schuurhuis Danita , Jacobs Joannes F.M. , Bol Kalijn , Schreibelt Gerty , Mus Roel , De Wilt Johannes H.W. , Haanen John B.A.G. , Schadendorf Dirk , Croockewit Alexandra , Blokx Willeke A.M. , Van Rossum Michelle M. , Kwok William W. , Adema Gosse J. , Punt Cornelis J.A. , Figdor Carl G.
Published: April 2023

Abstract
To evaluate the relevance of directing antigen-specific CD4+ T helper cells as part of effective anticancer immunotherapy, we investigated the immunologic and clinical responses to vaccination with dendritic cells (DC) pulsed with either MHC class I (MHC-I)–restricted epitopes alone or both MHC class I and II (MHC-I/II)–restricted epitopes. We enrolled 33 stage III and IV HLA-A*02:01–positive patients with melanoma in this study, of whom 29 were evaluable for immunologic response. Patients received intranodal vaccinations with cytokine-matured DCs loaded with keyhole limpet hemocyanin and MHC-I alone or MHC-I/II–restricted tumor-associated antigens (TAA) of tyrosinase and gp100, depending on their HLA-DR4 status. In 4 of 15 patients vaccinated with MHC-I/II–loaded DCs and 1 of 14 patients vaccinated with MHC-I–loaded DCs, we detected TAA-specific CD8+ T cells with maintained IFN-γ production in skin test infiltrating lymphocyte (SKIL) cultures and circulating TAA-specific CD8+ T cells. If TAA-specific CD4+ T-cell responses were detected in SKIL cultures, it coincided with TAA-specific CD8+ T-cell responses. In 3 of 13 patients tested, we detected TAA-specific CD4+CD25+FoxP3− T cells with high proliferative capacity and IFN-γ production, indicating that these were not regulatory T cells. Vaccination with MHC-I/II–loaded DCs resulted in improved clinical outcome compared with matched control patients treated with dacarbazine (DTIC), median overall survival of 15.0 versus 8.3 months (P = 0.089), and median progression-free survival of 5.0 versus 2.8 months (P = 0.0089). In conclusion, coactivating TAA-specific CD4+ T-helper cells with DCs pulsed with both MHC class I and II–restricted epitopes augments TAA-specific CD8+ T-cell responses, contributing to improved clinical responses. Cancer Res; 73(1); 19–29. ©2012 AACR.
Data from p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model
Authors: Chow Hoi Yee , Jubb Adrian M. , Koch Jennifer N. , Jaffer Zahara M. , Stepanova Dina , Campbell David A. , Duron Sergio G. , O'Farrell Marie , Cai Kathy Q. , Klein-Szanto Andres J.P. , Gutkind J. Silvio , Hoeflich Klaus P. , Chernoff Jonathan
Published: April 2023

Abstract
The RAS genes are the most commonly mutated oncogenes in human cancer and present a particular therapeutic dilemma, as direct targeting of Ras proteins by small molecules has proved difficult. Signaling pathways downstream of Ras, in particular Raf/Mek/Erk and PI3K/Akt/mTOR, are dominated by lipid and protein kinases that provide attractive alternate targets in Ras-driven tumors. As p21-activated kinase 1 (Pak1) has been shown to regulate both these signaling pathways and is itself upregulated in many human cancers, we assessed the role of Pak1 in Ras-driven skin cancer. In human squamous cell carcinoma (SCC), we found a strong positive correlation between advanced stage and grade and PAK1 expression. Using a mouse model of Kras-driven SCC, we showed that deletion of the mouse Pak1 gene led to markedly decreased tumorigenesis and progression, accompanied by near total loss of Erk and Akt activity. Treatment of KrasG12D mice with either of two distinct small molecule Pak inhibitors (PF3758309 and FRAX597) caused tumor regression and loss of Erk and Akt activity. Tumor regression was also seen in mice treated with a specific Mek inhibitor, but not with an Akt inhibitor. These findings establish Pak1 as a new target in KRAS-driven tumors and suggest a mechanism of action through the Erk, but not the Akt, signaling pathway. Cancer Res; 72(22); 5966–75. ©2012 AACR.
Data from Activation of Robo1 Signaling of Breast Cancer Cells by Slit2 from Stromal Fibroblast Restrains Tumorigenesis via Blocking PI3K/Akt/β-Catenin Pathway
Authors: Chang Po-Hao , Hwang-Verslues Wendy W. , Chang Yi-Cheng , Chen Chun-Chin , Hsiao Michael , Jeng Yung-Ming , Chang King-Jen , Lee Eva Y.-H.P. , Shew Jin-Yuh , Lee Wen-Hwa
Published: April 2023

Abstract
Tumor microenvironment plays a critical role in regulating tumor progression by secreting factors that mediate cancer cell growth. Stromal fibroblasts can promote tumor growth through paracrine factors; however, restraint of malignant carcinoma progression by the microenvironment also has been observed. The mechanisms that underlie this paradox remain unknown. Here, we report that the tumorigenic potential of breast cancer cells is determined by an interaction between the Robo1 receptor and its ligand Slit2, which is secreted by stromal fibroblasts. The presence of an active Slit2/Robo1 signal blocks the translocation of β-catenin into nucleus, leading to downregulation of c-myc and cyclin D1 via the phosphoinositide 3-kinase (PI3K)/Akt pathway. Clinically, high Robo1 expression in the breast cancer cells correlates with increased survival in patients with breast cancer, and low Slit2 expression in the stromal fibroblasts is associated with lymph node metastasis. Together, our findings explain how a specific tumor microenvironment can restrain a given type of cancer cell from progression and show that both stromal fibroblasts and tumor cell heterogeneity affect breast cancer outcomes. Cancer Res; 72(18); 4652–61. ©2012 AACR.
Data from SOCS3 Transactivation by PPARγ Prevents IL-17–Driven Cancer Growth
Authors: Berger Hélène , Végran Frédérique , Chikh Madijd , Gilardi Federica , Ladoire Sylvain , Bugaut Hélène , Mignot Grégoire , Chalmin Fanny , Bruchard Mélanie , Derangère Valentin , Chevriaux Angélique , Rébé Cédric , Ryffel Bernhard , Pot Caroline , Hichami Aziz , Desvergne Béatrice , Ghiringhelli François , Apetoh Lionel
Published: April 2023

Abstract
Activation of the transcription factor PPARγ by the n-3 fatty acid docosahexaenoic acid (DHA) is implicated in controlling proinflammatory cytokine secretion, but the intracellular signaling pathways engaged by PPARγ are incompletely characterized. Here, we identify the adapter-encoding gene SOCS3 as a critical transcriptional target of PPARγ. SOCS3 promoter binding and gene transactivation by PPARγ was associated with a repression in differentiation of proinflammatory T-helper (TH)17 cells. Accordingly, TH17 cells induced in vitro displayed increased SOCS3 expression and diminished capacity to produce interleukin (IL)-17 following activation of PPARγ by DHA. Furthermore, naïve CD4 T cells derived from mice fed a DHA-enriched diet displayed less capability to differentiate into TH17 cells. In two different mouse models of cancer, DHA prevented tumor outgrowth and angiogenesis in an IL-17–dependent manner. Altogether, our results uncover a novel molecular pathway by which PPARγ-induced SOCS3 expression prevents IL-17–mediated cancer growth. Cancer Res; 73(12); 3578–90. ©2013 AACR.
Data from Unexpected Dissemination Patterns in Lymphoma Progression Revealed by Serial Imaging within a Murine Lymph Node
Authors: Ito Ken , Smith Bryan Ronain , Parashurama Natesh , Yoon Joon-Kee , Song Si Yeol , Miething Cornelius , Mallick Parag , Lowe Scott , Gambhir Sanjiv Sam
Published: April 2023

Abstract
Non-Hodgkin lymphoma (NHL) is a heterogeneous and highly disseminated disease, but the mechanisms of its growth and dissemination are not well understood. Using a mouse model of this disease, we used multimodal imaging, including intravital microscopy (IVM) combined with bioluminescence, as a powerful tool to better elucidate NHL progression. We injected enhanced green fluorescent protein and luciferase-expressing Eμ-Myc/Arf−/− (Cdkn2a−/−) mouse lymphoma cells (EL-Arf−/−) into C57BL/6NCrl mice intravenously. Long-term observation inside a peripheral lymph node was enabled by a novel lymph node internal window chamber technique that allows chronic, sequential lymph node imaging under in vivo physiologic conditions. Interestingly, during early stages of tumor progression we found that few if any lymphoma cells homed initially to the inguinal lymph node (ILN), despite clear evidence of lymphoma cells in the bone marrow and spleen. Unexpectedly, we detected a reproducible efflux of lymphoma cells from spleen and bone marrow, concomitant with a massive and synchronous influx of lymphoma cells into the ILN, several days after injection. We confirmed a coordinated efflux/influx of tumor cells by injecting EL-Arf−/− lymphoma cells directly into the spleen and observing a burst of lymphoma cells, validating that the burst originated in organs remote from the lymph nodes. Our findings argue that in NHL an efflux of tumor cells from one disease site to another, distant site in which they become established occurs in discrete bursts. Cancer Res; 72(23); 6111–8. ©2012 AACR.